{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:44:58Z","timestamp":1761864298653},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s11912-021-01065-3","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T09:31:16Z","timestamp":1622799076000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need"],"prefix":"10.1007","volume":"23","author":[{"given":"F.","family":"Serra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Barruscotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Dominioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zuccarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Pedrazzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Chiellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"1065_CR1","unstructured":"Global Cancer Obseravatory \u2013 International Agency for Research on Cancer http:\/\/gco.iarc.fr\/."},{"issue":"4","key":"1065_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.sder.2010.10.005","volume":"29","author":"DS Rigel","year":"2010","unstructured":"Rigel DS. Epidemiology of melanoma. Semin Cutan Med Surg. 2010;29(4):204\u20139. https:\/\/doi.org\/10.1016\/j.sder.2010.10.005.","journal-title":"Semin Cutan Med Surg"},{"issue":"1","key":"1065_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2004.10.016","volume":"41","author":"S Gandini","year":"2005","unstructured":"Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41(1):45\u201360. https:\/\/doi.org\/10.1016\/j.ejca.2004.10.016.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1065_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1158\/1940-6207.CAPR-09-0108","volume":"3","author":"CM Olsen","year":"2010","unstructured":"Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: a meta-analysis of nevi and melanoma. Cancer Prev Res (Phila). 2010;3(2):233\u201345. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-09-0108.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"4","key":"1065_CR5","first-page":"572","volume":"7","author":"A Sandru","year":"2014","unstructured":"Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;7(4):572\u20136 PMC4316142.","journal-title":"J Med Life"},{"issue":"1","key":"1065_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1758834015616934","volume":"8","author":"Z Eroglu","year":"2016","unstructured":"Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016;8(1):48\u201356. https:\/\/doi.org\/10.1177\/1758834015616934.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"1065_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2217\/mmt-2017-0018","volume":"4","author":"E Simeone","year":"2017","unstructured":"Simeone E, Ascierto P. Anti-PD-1 and PD-L1 antibodies in metastatic melanoma. Melanoma Manag. 2017;4(4):175\u20138. https:\/\/doi.org\/10.2217\/mmt-2017-0018.","journal-title":"Melanoma Manag"},{"issue":"1","key":"1065_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014;4(1):94\u2013109. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0617.","journal-title":"Cancer Discov"},{"issue":"3","key":"1065_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/annonc\/mdz003","volume":"30","author":"E Borcoman","year":"2019","unstructured":"Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, et al. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30(3):385\u201396. https:\/\/doi.org\/10.1093\/annonc\/mdz003.","journal-title":"Ann Oncol"},{"issue":"20","key":"1065_CR10","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1002\/cncr.28851","volume":"120","author":"MM Chan","year":"2014","unstructured":"Chan MM, Haydu LE, Menzies AM, Azer MW, Klein O, Lyle M, et al. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. Cancer. 2014;120(20):3142\u201353. https:\/\/doi.org\/10.1002\/cncr.28851This paper represents one of the first studies as well as one of the most important on the topic of treatment beyond progression in patients with BRAF-mutated metastatic melanoma.","journal-title":"Cancer"},{"issue":"1","key":"1065_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/cam4.1267","volume":"7","author":"JC Hassel","year":"2018","unstructured":"Hassel JC, Buder-Bakhaya K, Bender C, Zimmer L, Weide B, Loquai C, et al. Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma. Cancer Med. 2018;7(1):95\u2013104. https:\/\/doi.org\/10.1002\/cam4.1267.","journal-title":"Cancer Med"},{"issue":"15","key":"1065_CR12","doi-asserted-by":"publisher","first-page":"12408","DOI":"10.18632\/oncotarget.10589","volume":"9","author":"P Queirolo","year":"2018","unstructured":"Queirolo P, Spagnolo F, Picasso V, Spano L, Tanda E, Fontana V, et al. Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. Oncotarget. 2018;9(15):12408\u201317. https:\/\/doi.org\/10.18632\/oncotarget.10589.","journal-title":"Oncotarget"},{"issue":"2","key":"1065_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(17)30846-X","volume":"19","author":"JA Beaver","year":"2018","unstructured":"Beaver JA, Hazarika M, Mulkey F, Mushti S, Chen H, He K, et al. An FDA pooled analysis of patients with melanoma treated with an Anti-PD1 antibody beyond RECIST progression. Lancet Oncol. 2018;19(2):229\u201339. https:\/\/doi.org\/10.1016\/S1470-2045(17)30846-XThis article, based on a large sample of patients, is the reference work for the study of immunotherapy beyond progression in metastatic melanoma.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1065_CR14","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","volume":"24","author":"D McDermott","year":"2013","unstructured":"McDermott D, Haanen J, Chen TT, Lorigan P, O'Day S. MDX010-20 Investigators. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial. Ann Oncol. 2013;24(10):2694\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdt291.","journal-title":"Ann Oncol"},{"key":"1065_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1758835919851663","volume":"11","author":"G Schvartsman","year":"2019","unstructured":"Schvartsman G, Taranto P, Glitza IC, Agarwala SS, Atkins MB, Buzaid AC. Management of metastatic cutaneous melanoma: updates in clinical practice. Ther Adv Med Oncol. 2019;11:1\u201316. https:\/\/doi.org\/10.1177\/1758835919851663.","journal-title":"Ther Adv Med Oncol"},{"key":"1065_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ejca.2019.05.015","volume":"116","author":"S Kreft","year":"2019","unstructured":"Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, et al. Efficacy of PD-1\u2013based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. Eur J Cancer. 2019;116:207\u201315. https:\/\/doi.org\/10.1016\/j.ejca.2019.05.015.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1065_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2217\/mmt-2017-0010","volume":"4","author":"CE Ochoa","year":"2017","unstructured":"Ochoa CE, Joseph RW. Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy. Melanoma Manag. 2017;4(3):143\u20135. https:\/\/doi.org\/10.2217\/mmt-2017-0010.","journal-title":"Melanoma Manag"},{"issue":"2","key":"1065_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/mmt-2017-0003","volume":"4","author":"A Gupta","year":"2017","unstructured":"Gupta A, Gomes F, Lorigan P. The role for chemotherapy in the modern management of melanoma. Melanoma Manag. 2017;4(2):125\u201336. https:\/\/doi.org\/10.2217\/mmt-2017-0003.","journal-title":"Melanoma Manag"},{"issue":"3","key":"1065_CR19","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3390\/jcm8030368","volume":"8","author":"S Wr\u00f3bel","year":"2019","unstructured":"Wr\u00f3bel S, Przyby\u0142o M, St\u0119pie\u0144 E. The clinical trial landscape for melanoma therapies. J Clin Med. 2019;8(3):368. https:\/\/doi.org\/10.3390\/jcm8030368This paper highlights the importance of clinical trials as a treatment option in patients with progressing metastatic melanoma.","journal-title":"J Clin Med"},{"key":"1065_CR20","doi-asserted-by":"publisher","unstructured":"Hanovich E, Asmis T, Ong M, Stewart D. Rechallenge strategy in cancer therapy. Oncology. 2020:1\u201311. https:\/\/doi.org\/10.1159\/000507816.","DOI":"10.1159\/000507816"},{"issue":"1","key":"1065_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1756-9966-32-92","volume":"32","author":"G Tonini","year":"2013","unstructured":"Tonini G, Imperatori M, Vincenzi B, Frezza AM, Santini D. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res. 2013;32(1):92. https:\/\/doi.org\/10.1186\/1756-9966-32-92.","journal-title":"J Exp Clin Cancer Res"},{"key":"1065_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.12.007","volume":"91","author":"S Valpione","year":"2018","unstructured":"Valpione S, Carlino MS, Mangana J, Gaba L, Long GV, Lorigan P, et al. Rechallenge with BRAF-directed treatment in metastatic melanoma: a multi-institutional retrospective study. Eur J Cancer. 2018;91:116\u201324. https:\/\/doi.org\/10.1016\/j.ejca.2017.12.007This work explains the rechallenge strategy with targeted therapy in advanced melanoma.","journal-title":"Eur J Cancer"},{"key":"1065_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/ddg.14091","volume":"18","author":"R Reschke","year":"2020","unstructured":"Reschke R, Ziemer M. Rechallenge with checkpoint inhibitors in metastatic melanoma. J Dtsch Dermatol Ges. 2020;18:429\u201336. https:\/\/doi.org\/10.1111\/ddg.14091This issue deals with the topic of rechallenge immunotherapy in metastatic melanoma.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"18","key":"1065_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3978\/j.issn.2305-5839.2015.08.06","volume":"3","author":"N Karachaliou","year":"2015","unstructured":"Karachaliou N, Pilotto S, Teixido C, Viteri S, Gonzalez-Cao M, Riso A, et al. Melanoma: oncogenic drivers and the immune system. Ann Transl Med. 2015;3(18):265. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.08.06.","journal-title":"Ann Transl Med"},{"key":"1065_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.phrs.2018.08.019","volume":"136","author":"M Kuske","year":"2018","unstructured":"Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C, et al. Immunomodulatory effects of BRAF and MEK inhibitors: implications for melanoma therapy. Pharmacol Res. 2018;136:151\u20139. https:\/\/doi.org\/10.1016\/j.phrs.2018.08.019.","journal-title":"Pharmacol Res"},{"issue":"47","key":"1065_CR26","doi-asserted-by":"publisher","first-page":"28294","DOI":"10.18632\/oncotarget.25511","volume":"9","author":"E Hajek","year":"2018","unstructured":"Hajek E, Krebs F, Bent R, Haas K, Bast A, Steinmetz I, et al. BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells. Oncotarget. 2018;9(47):28294\u2013308. https:\/\/doi.org\/10.18632\/oncotarget.25511.","journal-title":"Oncotarget"},{"key":"1065_CR27","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","volume":"21","author":"L Liu","year":"2015","unstructured":"Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1 and CTLA-4. Clin Cancer Res. 2015;21:1639\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2339.","journal-title":"Clin Cancer Res"},{"key":"1065_CR28","doi-asserted-by":"publisher","first-page":"9531","DOI":"10.1200\/JCO.2019.37.15_suppl.9531","volume":"15","author":"G Long","year":"2019","unstructured":"Long G, Lebbe C, Atkinson V, Mandal\u00e0 M, Nathan PD, Fernandez AMA, et al. The anti\u2013PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600\u2013mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i. J Clin Oncol. 2019;15:9531. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.9531This study is considered one of the pioneering trials for development of combined treatment strategies in metastatic melanoma.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1065_CR29","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1159\/000492272","volume":"98","author":"M Glatzer","year":"2020","unstructured":"Glatzer M, Panje CM, Sir\u00e9n C, Cihoric N, Putora PM. Decision making criteria in oncology. Oncology. 2020;98(6):370\u20138. https:\/\/doi.org\/10.1159\/000492272.","journal-title":"Oncology"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-021-01065-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-021-01065-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-021-01065-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T14:45:33Z","timestamp":1623941133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-021-01065-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s11912-021-01065-3","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"assertion":[{"value":"30 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francesco Serra, Stefania Barruscotti, Tommaso Dominioni, Andrea Zuccarini, and Paolo Pedrazzoli declare no conflict of interest. Silvia Chiellino has received compensation for service as a consultant from Bristol-Myers Squibb, MSD, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by the authors","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"84"}}